Skip to content
PeptideAgent

Clinics in New Jersey

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

What New Jersey law means for peptide clinics: who may prescribe, whether pharmacies may compound GLP-1 drugs (limited), how to check a clinic, and verified listings.

New Jersey at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async not allowed
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Verified clinics serving New Jersey

No verified clinics serving New Jersey are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Peptide access rules in New Jersey

Yes. A New Jersey resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a New Jersey-licensed prescriber, including through telemedicine under the Telemedicine and Telehealth Act (P.L.2017, c.117, N.J.S.A. 45:1-61 and following). A compounded peptide is available when it is eligible under federal 503A rules and dispensed by a pharmacy the New Jersey State Board of Pharmacy permits or registers. The Board has also taken an explicit position on GLP-1s: its 2023 statement on semaglutide compounding says no salt form of semaglutide may be used and requires pharmaceutical-grade semaglutide base from an FDA-registered source with a valid certificate of analysis. [1] [2] [3] [4] [5] [6] [7] [8] [9] [11]

Compounded GLP-1 access in New Jersey

Compounded semaglutide and tirzepatide are limited to the federal exception for documented patient specific needs because the FDA shortage allowances ended in 2025, and the Board's 2023 statement independently bars semaglutide salt forms and requires documented, FDA-registered sourcing of semaglutide base. [9] [14]

Research use only sellers in New Jersey

New Jersey's food and drug law (N.J.S.A. Title 24) prohibits selling adulterated or misbranded drugs, and the Pharmacy Practice Act limits dispensing to licensed pharmacies. The Board's semaglutide statement also warns pharmacies against non-pharmaceutical-grade ingredients. [9] [10] [15]

New Jersey notes on specific peptides

  • Semaglutide: Available branded by prescription, including by telemedicine under N.J.S.A. 45:1-61 and following. Compounded semaglutide is limited to the federal patient specific exception since April 22, 2025, and the New Jersey Board of Pharmacy bars any salt form of semaglutide in compounding. [9] [14]
  • BPC-157: Not FDA approved and not on the 503A bulks list. PCAC's July 2026 recommendation is advisory, and until FDA publishes a final rule a 503A pharmacy has no federal basis to compound it from bulk; a state board cannot authorize what federal law does not. New Jersey pharmacies apply the federal eligibility test and the Board's sourcing expectations for pharmaceutical-grade ingredients. [9] [12] [13]

How to check a clinic in New Jersey

  1. Confirm the prescribing clinician's license with the New Jersey medical or nursing board.
  2. Ask which pharmacy compounds or dispenses the peptide and check it in the New Jersey State Board of Pharmacy (Division of Consumer Affairs) license lookup. [1] [5] [6] [7] [9] [11]
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in New Jersey. [9] [10] [15]

Common questions in New Jersey

Can I get a GLP-1 prescription in New Jersey through telemedicine?

Yes, from a New Jersey-licensed provider. The Telemedicine and Telehealth Act lets providers establish a relationship and prescribe through telemedicine under the in-person standard of care, and semaglutide and tirzepatide are not controlled substances. [2] [3]

All peptide legal questions for New Jersey

Sources

  1. [1]New Jersey State Board of Pharmacy (Division of Consumer Affairs)
  2. [2]N.J.S.A. 45:1-61, Definitions relative to telemedicine and telehealth
  3. [3]N.J.S.A. 45:1-62, Provision of health care through telemedicine or telehealth; requirements
  4. [4]New Jersey P.L.2017, c.117 (S291), Telemedicine and Telehealth Act
  5. [5]New Jersey Pharmacy Practice Act, N.J.S.A. 45:14-40 and following, and N.J.A.C. 13:39 (Board laws and regulations)
  6. [6]N.J.S.A. 45:14-73, Registration of out-of-State pharmacies; requirements
  7. [7]N.J.A.C. 13:39-4.20, Out-of-State pharmacy registration
  8. [8]N.J.A.C. 13:35-6B.5, Provision of health care services through telemedicine or telehealth (Board of Medical Examiners)
  9. [9]New Jersey State Board of Pharmacy: Statement concerning semaglutide compounding (posted version dated November 6, 2023)
  10. [10]N.J.S.A. Title 24, Food and drugs